Merck & Co., Inc. (LON:MRK)

London flag London · Delayed Price · Currency is GBP · Price in GBX
58.00
0.00 (0.00%)
Mar 27, 2025, 4:35 PM BST
-17.73%
Market Cap 174.11B
Revenue (ttm) 51.26B
Net Income (ttm) 13.67B
Shares Out n/a
EPS (ttm) 5.38
PE Ratio 12.73
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 612,000
Average Volume 291,682
Open 58.80
Previous Close 58.00
Day's Range 58.00 - 58.80
52-Week Range 48.00 - 77.00
Beta 0.71
RSI 83.47
Earnings Date Apr 24, 2025

About Merck & Co.

Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The company offers human health pharmaceutical for various areas, including oncology, vaccines, hospital acute care, cardiovascular, virology, neuroscience, and diabetes under the Keytruda, Welireg, Gardasil, ProQuad, M−M−R II, Varivax, Vaxneuvance, RotaTeq, Pneumovax 23, Bridion, Dificid, Zerbaxa, Noxafil, Winrevair, Adempas, Verquvo, Lagevrio, Isentress/Isentress HD, Delstrigo, Pifeltro, Belsomra, Januvia, and Janu... [Read more]

Founded 1891
Employees 75,000
Stock Exchange London Stock Exchange
Ticker Symbol MRK
Full Company Profile

Financial Performance

In 2024, Merck & Co.'s revenue was $64.17 billion, an increase of 6.74% compared to the previous year's $60.12 billion. Earnings were $17.12 billion, an increase of 4589.59%.

Financial numbers in USD Financial Statements

News

Mike Ashley’s Frasers buys £3m stake in Marks Electrical

In a stock market filing, Marks revealed that Frasers has bought 6.73 million shares in the business.

4 months ago - Evening Standard

Three Quick Facts: AstraZeneca, Marks Electrical, BAE Systems

Buoyant demand sustains revenue growth at AstraZeneca, solid revenue growth at Marks Electrical, BAE Systems on track following upgrades

4 months ago - The Armchair Trader